Амтолметин гуацил. Можно ли создать улучшенный НПВП?
https://doi.org/10.21518/2079-701X-2013-12-84-89
Аннотация
Список литературы
1. Насонов Е.Л. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой // Клин. фармакол. и терапия. 2003. №12(1). С. 64-69.
2. Боль (практическое руководство для врачей) / под ред. Н.Н. Яхно, М.Л. Кукушкина. М.: Издательство РАМН, 2012.
3. Lee Y. Effect and treatment of chronic pain in inflammatory arthritis // Curr. Rheumatol. Rep. 2013. №15(1). Р. 300. van de Laar M. Pergolizzi J., Mellinghoff H. et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs // The Open Rheumatology Journal. 2012. №6. Р. 320-330.
4. Fiorucci S., Distrutti E. COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs // Curr. Med. Chem. 2011. №18(23). Р. 3494-3505.
5. Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events // Am. J. Gastroenterol. 2003. №98(8). Р 1725-1733.
6. Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with oste-oarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison // Lancet. 2007. №369. Р. 465-473.
7. Silverstein F. New strategies for the prevention of serious upper GI complication from NSAIDs: lessons from the MUCOSA trial // New stand. Arth. Care. 1996. №5. Р. 2-6.
8. Acevedo E., Castaneda O., Ugaz M. et al. Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. Scand // J. Rheumatol. 2001. №30. P. 19-24.
9. Roberts D., Miner P. Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease // Drug. Healthc. And Patient. Saf. 2011. №3. P. 1-8.
10. Gigante A., Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on keto-profen/omeprazole // Clin. Drug. Investig. 2012. №32(4). P. 221-233.
11. Bello A. DUEXIS® (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug // Ther. Adv. Musculoskelet. Dis. 2012. №4(5). P. 327–339.
12. Kulkarni S.K., Singh V.P. Licofelone: the answer to unmet needs in osteoarthritis therapy? // Curr. Rheumatol. Rep. 2008. №10(1). P. 43–48.
13. Lanas A. Role of nitric oxide in the gastrointestinal tract // Arthritis Research & Therapy. 2008. №10. Suppl. 2. P. 4. doi:10.1186/ar2465.
14. Keeble J., Moore P. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs // British Journal of Pharmacology. 2002. №137. P. 295–310.
15. Lanas A., García-Rodríguez L.A., Arroyo M.T. et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants // Am. J. Gastroenterol. 2007. №102(3). P. 507–515.
16. Lohmander L.S., McKeith D., Svensson O. et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis // Ann. Rheum. Dis. 2005. №64. P. 449–456.
17. Cordrey LJ. Tolmetin sodium, a new anti-arthritis drug: double-blind and long-term studies // Journal of the American Geriatrics Society. 1976. №24(10). P. 440–446.
18. AHFS Drug Information 2007. McEvoy G.K., ed. Tolmetin. Bethesda, MD // American Society of Health-System Pharmacists. 2007. P. 2118–2122.
19. Coruzzi G., Coppelli G., Spaggiari S. et al. Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible aastric nitric oxide svnthase // Dig Liver Dis. 2002. №34(6). 403–410.
20. Tubaro E., Belogi L., Mezzadri C.M. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug // European Journal of Pharmacology. 2000. №387. P. 233–244.
21. Morini G., Guaita E., Lazzaretti M. et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs // Digestion. 2003. №68(2–3). P. 124–132.
22. Riezzo G., Chiloiro M., Montanaro S. Protective effect of amtolmetin guacyl versus placebo diclofenac and misoprostol in healthy volunteers evaluated as gastric electrical activity in alcohol-induced stomach damage // Dig Dis Sci. 2001. №46(8). P. 1797–1804.
23. Tavella A., Ursini G. A clinical study on the anti-inflammatory activity and gastrointestinal tolerability of amtolmetin guacyl, a new NSAID, compared with diclofenac in aged patients with osteoarticular diseases. [Article in Italian] // Clin. Ter. 1997. №148(11). P. 543–548.
24. Marcolongo R., Frediani B., Biasi G. et al. A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents // Clin. Drug. Invest. 1999. №17(2). P. 89–96.
25. Jajić Z., Malaise M., Nekam K. et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis // Clin. Exp. Rheumatol. 2005. №23(6). P. 809–818.
26. Belisari A., Mantovani L. Cost-Benefit Analysis of Amtolmetin-Guacil // Clin. Drug. Invest. 2001.
Рецензия
Для цитирования:
Каратеев АЕ. Амтолметин гуацил. Можно ли создать улучшенный НПВП? Медицинский Совет. 2013;(12):84-89. https://doi.org/10.21518/2079-701X-2013-12-84-89
For citation:
Karateyev AE. Amtolmetin guacil: is it possible to develop an "advanced" NSAID? Meditsinskiy sovet = Medical Council. 2013;(12):84-89. (In Russ.) https://doi.org/10.21518/2079-701X-2013-12-84-89